XTL Biopharmaceuticals Ltd. (XTLB)

XTL Biopharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	0.15	0.37	1.4	2.09	2.97	3.63
Short-Term Investments	0.11	0.77	0.61	1.63	3.16	2.41
Cash & Short-Term Investments	0.26	1.14	2.01	3.72	6.13	6.04
Cash Growth	-83.67%	-43.02%	-46.09%	-39.27%	1.41%	-10.20%
Accounts Receivable	0.09	0.1	-	-	-	-
Other Current Assets	0.18	0.1	0.04	0.09	0.11	0.08
Total Current Assets	0.53	1.34	2.05	3.81	6.24	6.12
Net Property, Plant & Equipment	0.17	0.19	-	-	0	0
Other Intangible Assets	-	3.82	0.38	0.38	0.38	0.38
Goodwill	-	3.19	-	-	-	-
Other Long-Term Assets	0.01	0.01	-	-	-	-
Total Assets	0.71	8.55	2.43	4.19	6.62	6.5
Accrued Expenses	0.64	0.79	0.21	0.19	0.23	0.25
Short-Term Debt	0.09	0.14	-	-	-	-
Other Current Liabilities	0.04	1.28	-	-	-	-
Total Current Liabilities	0.76	2.21	0.21	0.19	0.23	0.25
Other Long-Term Liabilities	-	0.91	-	-	1.05	2.64
Total Long-Term Liabilities	-	0.91	-	-	1.05	2.64
Total Liabilities	0.76	3.12	0.21	0.19	1.29	2.89
Common Stock	23.14	23.14	14.12	14.12	14.12	13.18
Additional Paid-in Capital	141.29	141.29	146.33	146.33	146.33	146.02
Accumulated Other Comprehensive Income	0.02	0.02	0.02	0.02	0.02	0.02
Retained Earnings	-164.49	-159.01	-158.25	-156.47	-155.13	-155.61
Shareholders' Equity	-0.05	5.44	2.22	4	5.33	3.61
Total Liabilities & Equity	0.71	8.55	2.43	4.19	6.62	6.5
Total Debt	0.09	0.14	0	0	0	0
Net Cash (Debt)	0.17	1.01	2.01	3.72	6.13	6.04
Net Cash Growth	-82.79%	-49.90%	-46.09%	-39.27%	1.41%	-10.20%
Net Cash Per Share	0.02	0.14	0.37	0.68	0.99	1.18
Book Value	-0.05	5.44	2.22	4	5.33	3.61
Book Value Per Share	-0.01	0.77	0.41	0.73	0.87	0.70
Tangible Book Value	-0.05	-1.57	1.84	3.62	4.95	3.23
Tangible Book Value Per Share	-0.01	-0.22	0.34	0.66	0.80	0.63

Updated Jun 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q